Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Statin therapy showed no clear difference in hospitalisation due to heart failure compared with placebo or standard of care (low certainty).
The review found no eligible studies for this question.
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
Triple therapy showed no clear difference in all‐cause SAEs compared with LABA/LAMA combination (low certainty).
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether schema therapy changes reconviction Assessed by: number of participants documented to have… compared with treatment‐as‐usual (very low certainty).
The review found no eligible studies for this question.
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).